DNA
Price
$11.41
Change
-$0.12 (-1.04%)
Updated
Sep 25, 03:30 PM (EDT)
Capitalization
682.57M
LTRN
Price
$4.27
Change
-$0.31 (-6.77%)
Updated
Sep 25, 03:48 PM (EDT)
Capitalization
49.46M
41 days until earnings call
Interact to see
Advertisement

DNA vs LTRN

Header iconDNA vs LTRN Comparison
Open Charts DNA vs LTRNBanner chart's image
Ginkgo Bioworks Holdings
Price$11.41
Change-$0.12 (-1.04%)
Volume$200
Capitalization682.57M
Lantern Pharma
Price$4.27
Change-$0.31 (-6.77%)
Volume$100
Capitalization49.46M
DNA vs LTRN Comparison Chart in %
Loading...
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LTRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNA vs. LTRN commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNA is a Hold and LTRN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (DNA: $11.53 vs. LTRN: $4.58)
Brand notoriety: DNA and LTRN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNA: 61% vs. LTRN: 94%
Market capitalization -- DNA: $682.57M vs. LTRN: $49.46M
DNA [@Biotechnology] is valued at $682.57M. LTRN’s [@Biotechnology] market capitalization is $49.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $96.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNA’s FA Score shows that 1 FA rating(s) are green whileLTRN’s FA Score has 0 green FA rating(s).

  • DNA’s FA Score: 1 green, 4 red.
  • LTRN’s FA Score: 0 green, 5 red.
According to our system of comparison, DNA is a better buy in the long-term than LTRN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNA’s TA Score shows that 3 TA indicator(s) are bullish while LTRN’s TA Score has 4 bullish TA indicator(s).

  • DNA’s TA Score: 3 bullish, 5 bearish.
  • LTRN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, LTRN is a better buy in the short-term than DNA.

Price Growth

DNA (@Biotechnology) experienced а +4.16% price change this week, while LTRN (@Biotechnology) price change was +17.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.82%. For the same industry, the average monthly price growth was +8.53%, and the average quarterly price growth was +51.80%.

Reported Earning Dates

LTRN is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+0.82% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNA($683M) has a higher market cap than LTRN($49.5M). LTRN YTD gains are higher at: 43.574 vs. DNA (17.413). LTRN has higher annual earnings (EBITDA): -20.48M vs. DNA (-292.97M). DNA has more cash in the bank: 474M vs. LTRN (15.9M). LTRN has less debt than DNA: LTRN (145K) vs DNA (429M). DNA has higher revenues than LTRN: DNA (231M) vs LTRN (0).
DNALTRNDNA / LTRN
Capitalization683M49.5M1,380%
EBITDA-292.97M-20.48M1,430%
Gain YTD17.41343.57440%
P/E RatioN/AN/A-
Revenue231M0-
Total Cash474M15.9M2,981%
Total Debt429M145K295,862%
TECHNICAL ANALYSIS
Technical Analysis
DNALTRN
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 28 days ago
82%
Declines
ODDS (%)
Bearish Trend 29 days ago
86%
Bearish Trend 11 days ago
83%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
DNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LTRN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FSOAX44.35N/A
N/A
Fidelity Advisor Value Strategies A
AMVRX16.43-0.02
-0.12%
American Century Mid Cap Value R
HSMAX12.75-0.05
-0.39%
Hartford Small Cap Value A
JFACX38.96-0.19
-0.49%
JHancock Fundamental All Cap Core R2
JHISX13.45-0.07
-0.52%
Janus Henderson VIT Global Sust Eq Ins

DNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNA has been loosely correlated with RXRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if DNA jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNA
1D Price
Change %
DNA100%
-6.64%
RXRX - DNA
51%
Loosely correlated
+1.46%
ABCL - DNA
48%
Loosely correlated
-2.65%
ABSI - DNA
47%
Loosely correlated
-4.23%
CRSP - DNA
47%
Loosely correlated
+0.48%
NTLA - DNA
45%
Loosely correlated
+3.98%
More

LTRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LTRN has been loosely correlated with DNA. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LTRN jumps, then DNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LTRN
1D Price
Change %
LTRN100%
+12.53%
DNA - LTRN
34%
Loosely correlated
-6.64%
BMRN - LTRN
33%
Loosely correlated
+0.67%
HUMA - LTRN
33%
Loosely correlated
-1.18%
RLAY - LTRN
33%
Poorly correlated
+1.57%
MNMD - LTRN
32%
Poorly correlated
-1.31%
More